Literature DB >> 34997218

Human umbilical cord blood mesenchymal stem cells-derived exosomal microRNA-503-3p inhibits progression of human endometrial cancer cells through downregulating MEST.

Ying Pan1, Xue Wang1, Yang Li2, Peiyu Yan1, Hong Zhang3.   

Abstract

Endometrial cancer (EC) is a group of epithelial malignant tumors that occur in the endometrium. The specific pathogenesis is not revealed, hence, the goal of this study was to investigate the influence of human umbilical cord blood mesenchymal stem cells (hUMSCs)-derived exosomal microRNA-503-3p (miR-503-3p) on human EC cells by mediating mesoderm-specific transcript (MEST). The binding relationship between MiR-503-3p and MEST was searched. HUMSCs were collected and exosomes (Exos) were isolated and identified. Human EC cell lines HEC-1B and RL95-2 were transfected with elevated miR-503-3p or silenced MEST vector or co-cultured with Exos to figure their roles in biological functions of EC cells. The in vitro effect of miR-503-3p, MEST, and Exos on EC cells was further verified in vivo. MEST was a target of miR-503-3p. Overexpression of miR-503-3p or reduction of MEST suppressed the biological functions of EC cells. Enhanced MEST expression mitigated the role of upregulated miR-503-3p on the growth of EC cells. HUMSCs-derived Exos suppressed EC cell growth, upregulated miR-503-3p-modified HUMSCs-derived Exos had a more obvious inhibitory effect on EC cell growth. The anti-tumor effect of elevated miR-503-3p, silenced MEST, and HUMSCs-derived Exos were verified in nude mice. This study highlights that hUMSCs-derived exosomal miR-503-3p inhibits EC development by suppressing MEST, which is of great benefit to EC therapy.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34997218     DOI: 10.1038/s41417-021-00416-3

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  4 in total

1.  LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis.

Authors:  Guangyu Zhang; Anjun Ma; Yuqin Jin; Guoyou Pan; Cong Wang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

2.  ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription.

Authors:  Yan-Yi Xiao; Li Lin; Yong-Hao Li; Hui-Ping Jiang; Li-Tong Zhu; Yuan-Run Deng; Dan Lin; Wei Chen; Cheng-Ying Zeng; Li-Jing Wang; Shao-Cheng Chen; Qing-Ping Jiang; Chun-Hua Liu; Wei-Yi Fang; Sui-Qun Guo
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

3.  Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo.

Authors:  Christopher S Gondi; Krishna Kumar Veeravalli; Bharathi Gorantla; Dzung H Dinh; Dan Fassett; Jeffrey D Klopfenstein; Meena Gujrati; Jasti S Rao
Journal:  Neuro Oncol       Date:  2010-01-22       Impact factor: 12.300

4.  Stemness-Attenuating miR-503-3p as a Paracrine Factor to Regulate Growth of Cancer Stem Cells.

Authors:  Minkoo Seo; Seung Min Kim; Eun Young Woo; Ki-Cheol Han; Eun Joo Park; Seongyeol Ko; Eun Wook Choi; Mihue Jang
Journal:  Stem Cells Int       Date:  2018-04-04       Impact factor: 5.443

  4 in total
  3 in total

Review 1.  Exosomes on Endometrial Cancer: A Biomarkers Treasure Trove?

Authors:  Alexandros G Sykaras; Konstantinos Christofidis; Ekaterini Politi; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

Review 2.  Immunological Changes in Pregnancy and Prospects of Therapeutic Pla-Xosomes in Adverse Pregnancy Outcomes.

Authors:  Himadri Devvanshi; Rohit Kachhwaha; Anima Manhswita; Shinjini Bhatnagar; Pallavi Kshetrapal
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

Review 3.  Advances in Exosomes as Diagnostic and Therapeutic Biomarkers for Gynaecological Malignancies.

Authors:  Mengdan Miao; Yifei Miao; Yanping Zhu; Junnan Wang; Huaijun Zhou
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.